Rucaparib (AG-014699,PF-01367338) phosphate

Catalog No.S1098

Rucaparib (AG-014699,PF-01367338) phosphate Chemical Structure

Molecular Weight(MW): 421.36

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 17 Publications

8 Customer Reviews

  • Representative images for RAD51 and γH2AX foci formation, surrogate DSB markers, in stable shK-H or shSCR 231 cells after rucaparib or vehicle (0.01% DMSO) treatment for 24 hours. DAPI-stained cell nuclei. Scale bars, 10 μm.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-17-1118. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

    MDA-MB-231 cells were inoculated into mammary fad pad of nude mice, and the mice with established tumors were treated with olaparib or rucaparib. Tumors were then isolated to evaluate PD-L1 expression by IHC staining (C). Black arrowheads indicate the detected PD-L1 signals. Scale bar, 50 μm.

    Clin Cancer Res, 2017, 23(14):3711-3720. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

  • For anchorage dependent clonogenic assays, HER2+ breast cancer BT474 cells were seeded at low density in 6-well plates and allowed to adhere overnight. The next day, olaparib and rucaparib were added at the indicated concentrations. Media and drugs were replenished every three days. After 10-15 days, depending on cell proliferation rate, cells were fixed and stained with crystal violet. Images and graphs indicate the results compared to control condition. Data are mean ± S.D. n.s.: non-significant, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

    Eur J Cancer 2014 50(15), 2725-34. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

    Total cell extracts of BT-474 cells treated with increasing concentrations of olaparib or rucaparib were subjected to western blot analysis for PARP-1 and poly ADP-ribose (PAR) expression. β-tubulin was used as loading control. Representative images from two separate experiments are shown.

    Eur J Cancer 2014 50(15), 2725-34. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

  • Three sensitive and three resistant cell lines were treated for 24 h with 0.02% DMSO (negative control) or 10 uM rucaparib. Serving as positive control were cells fixed 30 min after exposure to 2 Gy IR. Image acquisition was performed with a confocal microscope (Leica TCS SP2) using the 100X objective and a 2X optical zoom and oil immersion. Red: γH2AX foci. Green: RAD51 foci. *P < 0.05 **P < 0.01 ***P < 0.001. Fluorescence microscopy images of DAPI-stained rucaparib-sensitive (HN4) and rucaparib-resistant (SAS) HNC cell lines treated with DMSO, 2 Gy or 10 uM rucaparib for 24 h.

    Oral Oncol 2014 50(9), 825-31. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

    purified PARP-1 and His-XPA were incubated alone ( lane 7 ), with activated PARP-1 (addition of activated DNA and NAD+, lane 8 ), or in the presence of the PARP inhibitor AG-014699 (lane 9 ). Following the various treatments, His-XPA was pulled down ( IP ) from each sample using cobalt-conjugated magnetic beads.

    J Biol Chem 2012 287, 39824-33. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

  • Antitumor effects of transfecting of INPP4B gene combined with PARP inhibitor treatment on PC3 cells. (A) The change of cell number and shape under the microscope. (B) The viability of PC3 cells measured using CCK-8. (C) The cell cycle phase distribution of PC3 detected by flow cytometry. (D) Apoptosis of PC3 cells detected using annexin V-FITC/PI staining. (Asterisks denote statistical significance between Lenti-INPP4B+PARP inhibitor and Lenti-INPP4B and PARP inhibitor treatment, *P<0.05).

    Urol Oncol 2014 32(5), 720-6. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AG-014699 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AG-014699 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    Dr. David Schrmann from University of Base. Rucaparib (AG-014699,PF-01367338) phosphate purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
Features The first PARP inhibitor used in clinical trials combined with temozolomide.
Targets
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
In vitro

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 NIjMcGFHfW6ldHnvckBCe3OjeR?= NGPC[3ExNjFxMT:1NFAwOTByMDDuUS=> MV\pcohq[mm2czDQRXJRKGGldHn2bZR6KGG2IIP0ZZJ1cW6pIHPvcoNmem62cnH0bY9vKG:oIEWwNEBvVQ>? M13zTFI2OTJ6NEW1
BT474 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PjclUxOCCwTR?= NF3DN5YyOOLCk{G1xsBl MmXGdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> Mn2yNlUyOjh2NUW=
SKBR3 M1XlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PuelUxOCCwTR?= M1POfFEx6oDVMUZCpIQ> NV\NbWdnemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? MnfGNlUyOjh2NUW=
AU565 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYS1NFAhdk1? MmDSNVDjiJNzNdMg[C=> Mom4doVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> NX65V5BzOjVzMki0OVU>
EFM192A MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO3OItEPTByIH7N NEfHNI8yOOLCk{G1xsBl M{jHbJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> MUCyOVEzQDR3NR?=
MDA-MB-231 M{nWTGZ2dmO2aX;uJGF{e2G7 NWjEXmtnOTBxMkCvOFAh|ryP M2PudlI1KGh? M1P6VYlv[3KnYYPld{BxNUGNVDDs[ZZmdHNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWK1UlQxOjR2MkCxOVI>
MDA-MB-231 MmnDR4VtdCCYaXHibYxqfHliQYPzZZk> M1;rSVAvOS12MDFOwG0> NW\uUmNKOjRiaB?= MWHJR|Ux6oDLPfMAjVE4Njd5wrFOwG0> M2fzNVI1PDJyMUWy
MDA-MB-231 Mn\LRZBweHSxc3nzJGF{e2G7 MVexNE8zOC92MDFOwG0> M1W5[lI1KGh? NIjUXpBqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NITL[WozPDR{MEG1Ni=>
MDA-MB-231 NVLLXIRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rUXFExNzJyL{SwJO69VQ>? MUCyOEBp NYXFRlhT[myxY3vzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25iaX6gS|IwVSCyaHHz[S=> NGnLZnYzPDR{MEG1Ni=>
H460 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXtd5Z7PDByIH7N MlTwNlTDqGh? M2LjZolv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5 M3PLXVI1PDFzNkGx
A549  Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO2OFAxKG6P M{DmcVI1yqCq MV\pcoNz\WG|ZYOgZ4VtdHWuYYKgdoFlcW:|ZX7zbZRqfmm2eR?= NWTqXFB2OjR2MUG2NVE>
DT40 NUSzWYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXs[|l6UUN3ME2yNUBvVQ>? NYHmeZZtOjR|NU[4NVM>
DU145 NEW3WHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LVNGlEPTB;MUigcm0> M{f0SFI1OzV4OEGz
COLO704 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF71eI9KSzVyPUKuOVIhyrFiMD62O{DPxE1? M4PMOlI{PzJ7NECy
OVMANAb M{jHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jjbmlEPTB;Mj61PEDDuSByLkO4JO69VQ>? Ml:xNlM4Ojl2MEK=
OV177 M1K1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LO[GlEPTB;Mj63PEDDuSByLkexJO69VQ>? MkS2NlM4Ojl2MEK=
OAW28 NUPyU5p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHGTWM2OD1|Lk[xJOKyKDBwMkig{txO NFu0XIkzOzd{OUSwNi=>
OVSAHO M4jEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG3VWF5UUN3ME2zMlY1KMLzIECuN|Mh|ryP M4T5[FI{PzJ7NECy
OVKATE MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTZPYlEUUN3ME2zMlY1KMLzIEGuO|kh|ryP NWn0TWpZOjN5Mkm0NFI>
OVCAR3 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXUTWM2OD1|Lke0JOKyKDBwNECg{txO NGfqW3EzOzd{OUSwNi=>
PEO14 NETYdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXYTWM2OD1|Lki0JOKyKDBwN{[g{txO MWOyN|czQTRyMh?=
A2780 NUnVVVhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjmR29KSzVyPUOuPVQhyrFiMD6yOUDPxE1? M2DvXlI{PzJ7NECy
OVTOKO NVKzOHhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTRwMUSgxtEhOS53MzFOwG0> NGDwXGozOzd{OUSwNi=>
KURAMOCHIb MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnGTWM2OD12LkO0JOKyKDBwMkmg{txO NYTKV45WOjN5Mkm0NFI>
TOV21G M1:zSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjTVmpKSzVyPUWuNFchyrFiMT6zNEDPxE1? MXGyN|czQTRyMh?=
OVISE NHzKXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmftTWM2OD13Lk[4JOKyKDBwMkOg{txO NEDQZW8zOzd{OUSwNi=>
KK MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjtd3pKSzVyPU[uNVUhyrFiMT60NkDPxE1? MV[yN|czQTRyMh?=
RMUGS NHnEbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq2NFBKSzVyPUeuNFMhyrFiMT64N{DPxE1? M1e4R|I{PzJ7NECy
PEO6 MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTdwME[gxtEhOC55NDFOwG0> NFHTfJMzOzd{OUSwNi=>
OVCA429 NWT0TWFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHXTWM2OD16LkK5JOKyKDFwNkSg{txO MWSyN|czQTRyMh?=
OV167 NF3P[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHmTWM2OD16LkOzJOKyKDFwMUig{txO MljONlM4Ojl2MEK=
RMG1 MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTlwM{KgxtEhOi5|NjFOwG0> M1G2VVI{PzJ7NECy
OVCAR5 NG\GdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vnRWlEPTB;OT61NEDDuSB{LkW5JO69VQ>? MXeyN|czQTRyMh?=
EFO21 M1SzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTlwOUKgxtEhOS56NzFOwG0> MUiyN|czQTRyMh?=
ES2 NVy3ZmJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nM[GlEPTB;MUCuNVIhyrFiMT6yN{DPxE1? NF7De|YzOzd{OUSwNi=>
Tyk-nu MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID3Wm1KSzVyPUGwMlIxKMLzIEGuNVIh|ryP NHH6V2EzOzd{OUSwNi=>
CAOV3 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rmWGlEPTB;MUCuN|chyrFiMD64O{DPxE1? NYPTZlM{OjN5Mkm0NFI>
OV207 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rqN2lEPTB;MUKuNlchyrFiMD6zNkDPxE1? MkTNNlM4Ojl2MEK=
HEY Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF|LkCxJOKyKDBwN{Wg{txO MX2yN|czQTRyMh?=
DOV13 NYLzN49yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Dk[WlEPTB-MUWg{txO NUXwd4x4OjN5Mkm0NFI>
EFO27 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO0TWM2OD5zNTFOwG0> MojnNlM4Ojl2MEK=
HEY C2 NVmxboViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLEbXFKSzVyPkG1JO69VQ>? M4fZWFI{PzJ7NECy
KOC-7cc NXnYdnB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrMTWM2OD5zNTFOwG0> M1y2bFI{PzJ7NECy
MCASb M3HxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL4OmNKSzVyPkG1JO69VQ>? M3LwTlI{PzJ7NECy
OAW42 Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRjF3IN88US=> NHe1d2QzOzd{OUSwNi=>
OV2008 M3y0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRjF3IN88US=> MVKyN|czQTRyMh?=
OV90 NVHTbpJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLZRlJqUUN3ME6xOUDPxE1? MlnpNlM4Ojl2MEK=
OVCA420b NGjVT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfqWWVKSzVyPkG1JO69VQ>? NH;hOHgzOzd{OUSwNi=>
OVCA432 NVLJW4xpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRjF3IN88US=> MWKyN|czQTRyMh?=
PEA2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDzbFdjUUN3ME6xOUDPxE1? MXKyN|czQTRyMh?=
SKOV3 NHrURWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRjF3IN88US=> MWKyN|czQTRyMh?=
TOV112D NUP6cXFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfjWFAxNTNizszN NIjiRoxKSzVyPkG1JO69VQ>? MViyN|czQTRyMh?=
C4-2 NGjKXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG3NE0{KM7:TR?= NEjleY0yPCCm MlnSSG1UVw>? Ml\n[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? M{DkVFI{PTZ3MkS0
PC3 NEjpbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\oVW5uOC1|IN88US=> M{fWdVE1KGR? MlLaSG1UVw>? M{OwRYRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? MkWyNlM2PjV{NES=
DU145 NV3sPG5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\PdFAuOyEQvF2= NVvXb|R1OTRiZB?= MmTuSG1UVw>? NVTIc4Zj\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= Ml[1NlM2PjV{NES=
VCaP  NFPLfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[wMVMh|ryP NVTC[XBZOTRiZB?= NHPyPG1FVVOR NFvpZ2Jl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 MYeyN|U3PTJ2NB?=
LNCaP  M1TZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDURYkxNTNizszN Ml7oNVQh\A>? M{nQRmROW09? MVXk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 NXPEVVA6OjN3NkWyOFQ>
MDA-MB-468 NFrveJFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVrJR|UxRTlwNzFOwG0> MViyNlY4QDF4MR?=
MDA-MB-231 NXTUVFFzS2WubDDWbYFjcWyrdImgRZN{[Xl? MVzJR|UxRTF|IN88US=> NFzpSWszOjZ5OEG2NS=>
Cal-51 NHf2RnVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1jKVGlEPTB;OD62JO69VQ>? M2KyXVIzPjd6MU[x

... Click to View More Cell Line Experimental Data

In vivo Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

Protocol

Kinase Assay:[1]
+ Expand

Ki Determination:

Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
Cell Research:[4]
+ Expand
  • Cell lines: D425Med, D283Med and D384Med cells
  • Concentrations: 0.4 μM
  • Incubation Time: 3 or 5 days
  • Method: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CD-1 nude mice bearing established D283Med xenografts
  • Formulation: Normal saline
  • Dosages: 1 mg/kg
  • Administration: One or four daily by i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.36
Formula

C19H18FN3O.H3PO4

CAS No. 459868-92-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03694262 Not yet recruiting Endometrial Cancer Medical College of Wisconsin April 1 2019 Phase 2
NCT03694262 Not yet recruiting Endometrial Cancer Medical College of Wisconsin April 1 2019 Phase 2
NCT03840200 Not yet recruiting Breast Cancer|Prostate Cancer|Ovarian Cancer Hoffmann-La Roche March 22 2019 Phase 1|Phase 2
NCT03795272 Not yet recruiting Cervical Cancer Nordic Society for Gynaecologic Oncology|Institute of Cancer Research United Kingdom|Central and Eastern European Oncology Group|North Eastern Germany Society of Gynaecologic Oncology|Belgian Gynaecological Oncology Group|Princess Margaret Hospital Canada|PGOG (Polish Gynaecologic Oncology Group)|GSO Global Clinical Research BV|GCP-enhederne March 1 2019 Phase 2
NCT03639935 Recruiting Biliary Tract Cancer University of Michigan Rogel Cancer Center|Dana-Farber Cancer Institute|Vanderbilt University Medical Center March 2019 Phase 2
NCT03617679 Recruiting Metastatic Endometrial Cancer University of Colorado Denver|Clovis Oncology Inc.|National Cancer Institute (NCI) March 6 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Tags: buy Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate supplier | purchase Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate cost | Rucaparib (AG-014699,PF-01367338) phosphate manufacturer | order Rucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID